The Food and Drug Administration has approved Unloxcyt (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma.

Considering the susceptibility and infection rate of transmasculine individuals and cis-gender women are comparable; ...

Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Peritoneal Cancer.

Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase I for Non-Hodgkin Lymphoma.

Investigators sought to determine the safety and accuracy of remote cutaneous confocal microscopy vs histopathological diagnosis of melanoma and keratinocyte carcinoma.

Diffuse normolipemic plane xanthoma is characterized by large, yellow-brown flat, xanthomatous skin lesions usually involving the eyelids, sides of the neck, upper trunk, buttocks, and the ...

Skin-related adverse reactions are frequent with ICIs, with toxic epidermal necrolysis (TEN) being a severe and potentially life-threatening cutaneous reaction. Case presentation: We present a case of ...

The Food and Drug Administration (FDA) has approved Unloxcyt™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC ...

An FDA approval was granted for cosibelimab-ipdl for the treatment of patients with locally advanced or metastatic cutaneous squamous cell carcinoma. Cosibelimab-ipdl (Unloxcyt) has been granted FDA ...

for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. UNLOXCYT is ...

Detailed price information for Fortress Biotech Inc (FBIO-Q) from The Globe and Mail including charting and trades.

Indoor tanning exposure was not associated with tumor mutational burden (TMB) in patients with cutaneous melanoma ... sun exposure may be a greater primary driver of TMB than intermittent ...